SKNY-1, a THCV Analog, Reduces Weight, Normalizes Lipids, and Attenuates Reward Behaviors in Obese Zebrafish

Obesity is a complex disorder marked by dysregulated energy balance, altered lipid metabolism, and maladaptive reward processing. Loss-of-function mutations in the melanocortin-4 receptor (MC4R) are a common monogenic cause, leading to hyperphagia and altered energy expenditure. While non-selective CB1 antagonism can induce weight loss, prior clinical attempts like rimonabant faced severe neuropsychiatric side effects. This highlights a need for novel cannabinoid strategies with pathway-selective modulation.

Researchers investigated SKNY-1, a Δ9-Tetrahydrocannabivarin (THCV) analog, in an mc4r(G894C) zebrafish model of obesity. This model mimics human MC4R loss-of-function mutations, which are a prevalent genetic cause of severe early-onset obesity. The study aimed to evaluate the compound's effects on key obesity-related phenotypes, including body weight, lipid metabolism, and reward-associated behaviors. Specific dosing regimens, duration, and detailed assay methodologies were not provided in the available abstract.

Treatment with SKNY-1 demonstrated significant improvements across multiple metabolic and behavioral parameters in the obese zebrafish model. > The primary findings indicated a clear reduction in body weight, suggesting a positive impact on energy balance. Furthermore, SKNY-1 normalized lipid profiles, addressing the dysregulated lipid metabolism characteristic of obesity. Beyond metabolic effects, the analog also attenuated reward-associated behaviors, a critical aspect of MC4R-related obesity pathophysiology. These results suggest that SKNY-1 may modulate both metabolic control circuits and mesolimbic reward pathways, without specific quantitative data provided in the abstract.